Travere Therapeutics, Inc.

This study tests an experimental drug called sparsentan in 67 children with certain kidney diseases that cause protein leakage in urine. The goal is to see if the drug safely reduces protein levels over 108 weeks. Participants take the drug once daily as a liquid or tablet, and r…

This study tests a drug called sparsentan in 20 adults who have protein in their urine after a kidney transplant due to IgA nephropathy or FSGS. Participants take one pill daily for 36 weeks to see if it safely lowers protein levels and protects kidney function. The goal is to co…

This study tests a new drug called pegtibatinase for people with classical homocystinuria, a rare genetic condition that causes dangerously high levels of homocysteine in the blood. About 70 participants aged 12 to 65 will receive either the drug or a placebo alongside their usua…